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Background: Gastric cancer with synchronous liver metastasis remains a clinical treatment challenge. There has
been a longstanding debate on the question whether surgical resection could be beneficial to long-term survival.
This study is to investigate the effectiveness and prognostic factors of combined curative resection of the stomach
and liver lesions in gastric cancer patients with synchronous liver metastases.
Methods: A total of 30 patients who underwent simultaneous curative gastric and liver resection from March 2003
to April 2008 were analyzed retrospectively. Univariate and multivariate analyses were performed to select
independent factors for survival.
Results: The overall 1-, 2-, 3- and 5-year survival rates of 30 patients were 43.3%, 30.0%, 16.7% and 16.7%,
respectively, with a median survival of 11.0 months and 5 patients still living by the time of last follow-up. Single
liver metastasis (p = 0.028) and an absence of peritoneal dissemination (p = 0.007) were significantly independent
prognostic factors for these gastric cancer patients with synchronous liver metastases. Major adverse events were
protracted stomach paralysis in 2 patients and pulmonary infection in another 2 patients, all of whom recovered
after conservative treatment.
Conclusions: This descriptive study without control group found that patients with solitary liver metastasis and
absence of peritoneal dissemination could have better survival benefit from simultaneous curative resection of the
gastric cancer and liver metastases.
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Liver is one of the most frequent sites of cancer metasta-
sis from gastrointestinal origin, and the major cause of
disease death from stomach cancer [1]. The 5-year sur-
vival rate could be up to 29% for metachronous liver
metastasis and only 6% for synchronous liver metas-
tasis, from gastric cancer [2]. Therefore, it has long been
thought by many that surgical treatment could not
bring any substantial survival benefit for gastric cancer* Correspondence: shen.kuntang@zs-hospital.sh.cn
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reproduction in any medium, provided the orpatients with synchronous liver metastasis. However,
there has also been longstanding debate on the question
whether surgical resection could be beneficial to long-
term survival. Some believe that if R0 resection could be
performed for both gastric cancer and synchronous liver
metastasis, such simultaneous resection could signifi-
cantly improve survival [3,4]. On the other hand, gastric
cancer patients with liver metastasis usually have mul-
tiple intrahepatic lesions, peritoneal metastasis, regional
lymph nodes metastasis and adjacent organs involve-
ments [5-7], making it questionable whether simultan-
eous resection could bring any survival benefit. From
March 2003 to April 2008, we performed simultaneoustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on 30 patients. This study is to summarize our experi-
ence and to analyze the efficacy and prognosis on these
patients.
Methods
The study complied with the declaration of Helsinki and
was approved by Biomedical Research Ethics Committee of
Zhongshan Hospital of Fudan University (NO.2009-160).
All subjects gave written informed consent.
Patients and treatment
From March 2003 to April 2008, a total of 2942 patients
with gastric cancer were treated at our institution. From
the archived medical records, a complete database was
established on 30 gastric cancer patients with synchron-
ous liver metastasis, who had simultaneous complete re-
section of both gastric cancer and liver metastasis. The
database covered all clinico-pathological characteristics.
Lymph node grouping was based on Japanese classifica-
tion on cancer typing [8] and TNM classification was
base on AJCC 7th edition [9].
Of these 30 patients were 27 males and 3 females, with
age ranging from 33 to 72 years old (median 60 yr). The
primary stomach cancer was located at the antrum in 11
cases, at the gastric body in 9 cases and at the cardia-
fundus region in 10 cases. On local invasion status, 4
cases had tumor invasion beneath the serosa, and the
remaining 26 cases all had tumor invasion beyond theFigure 1 Median survival in 30 patients. Kaplan-Meier survival curve of t
after the simultaneous curative resection of the stomach and liver metastasserosa. On lymph nodes status, 7 cases did not have
lymph nodes metastasis while the remaining 23 cases
were lymph nodes positive. In terms of liver metastasis,
22 patients had one intrahepatic metastasis lesion and 8
patients had 2–3 liver metastases. There were 27
patients with metastasis limited to one lobe of the liver
(H1), and 3 cases with metastasis on both lobes of the
liver (H2). Simultaneous peritoneal metastasis was found
in 5 patients. Of surgical approaches, 11 patients had
curative distal gastrectomy, 10 patients had curative
proximal gastrectomy and 9 cases had total gastrectomy.
For liver resection, 7 patients had lobectomy and 23
patients had partial hepatectomy. These patients did not
receive any preoperative chemotherapy, but all patients
had postoperative adjuvant chemotherapy by experi-
enced oncologists.
Follow-up
All patients were regularly followed-up by telephone,
with the last follow-up on April 14, 2012. The survival
was calculated from the date of surgery to the date of
death or last follow-up. There were 25 cases died, all
due to cancer recurrence.
Statistical analysis
All the data were analyzed with SPSS 16.0 software. The
survival was analyzed by Kaplan-Meier and log rank test.
Cox regression model analysis was performed for uni-
variate and multivariate analysis, so as to discoverhe 30 patients in this study showed a median survival of 11.0 months
es.
Table 1 Clinico-pathological features on 30 patients in
this study
Age (yr)




Gastric cancer site: n (%)
Gastric antrum 11 (36.7%)
Gastric body 9 (30.0%)
Gastric cardia-fundus 10 (33.3%)




Gastric cancer diameter: cm
Median (Range) 3.7 (1.0—11.0)
Pathological type: n (%)
Papillary adenocarcinoma 13 (43.3%)
Tubular adenocarcinoma 10 (33.3%)
Poorly differentiated adenocarcinoma 4 (13.3%)
Mucinous adenocarcinoma 3 (10.0%)
Number of intrahepatic metastases: n (%)
Single metastastic lesion 22 (73.3%)
Multiple metastatic lesions 8 (26.7%)
Diameter of intrahepatic metastasis lesions: cm
Median (Range) 3.1 (0.5—16.0)
Surgical approaches: n (%)
Distal gastrectomy 11 (36.7%)
Total gastrectomy 9 (30.0%)
















Table 1 Clinico-pathological features on 30 patients in
this study (Continued)
Tumor differentiation: n (%)
Well differentiated 2 (6.67%)
Intermediately differentiated 5 (16.7%)
Poorly differentiated 23 (76.7%)
Survival status: n (%)
Survived 5 (16.7%)
Died 25 (83.3%)
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considered as statistically significant.
Results
Perioperative features
There were 14 (46.7%) cases with blood transfusion
(300–1000 mL, median 520 mL), 24 (80.0%) cases with
albumin transfusion (20–100 g, median 43 g), and 12
(40.0%) cases with parenteral nutrition support. Two
(6.7%) patients had gastric paralysis after operation and
subsequently recovered after nasogastric tube depression
for 19 and 22 days, respectively. Two (6.7%) patients had
pulmonary infection, one with A. baumanii and treated
with antibiotics for 49 days, and the other one infected
with Klebsiella pneumoniae and treated for 10 days with
anti-infection agents, and both were recovered well.
There were no perioperative deaths.
Follow-up Results
All 30 patients had complete follow-up data. By the time
of last follow-up, 25 (83.3%) patients died and 5 (16.7%)
patients were living, with median survival of 11.0
months (95% CI 7.8 to 14.2 months). The 1-, 2-, 3- and
5-year survival rates were 43.3%, 30.0%, 16.7% and 16.7%,
respectively (Figure 1). One patient with gastric ulcera-
tive hepatoid adenocarcinoma (pT2N2M1) lived for 107
months without evidence of recurrence.
Analysis on survival related independent factors
Table 1 summarized the correlation of major clinico-
pathological factors with survival status. Age, gender,
tumor marker levels (CEA, AFP and CA19-9), primary
tumor size, liver metastasis lesion size, tumor emboli, as-
cites, T staging and N staging all had no significant cor-
relation with survival, but the number of liver metastatic
lesions (log rant test, p = 0.028, Table 2, Figure 2) and peri-
toneal metastasis (log rant test, p = 0.007, Table 2, Figure 3)
were significantly correlated with survival. Multivariate
Cox regression survival analysis also confirmed that num-
ber of liver metastasis and peritoneal metastasis were
independent prognostic factors (Table 3).
Table 2 Survival analysis
Items N (survival rate) Log
rank p
HR 95% CI P
Age: (yr)
≤ 60 yr 15 (13.3%) 0.617 0.822 0.374-
1.808
0.627
> 60 yr 15 (20.0%)
Gender: n(%)

























< 5cm 18 (22.2%) 0.984 1.008 0.454-
2.236
0.985
≥ 5cm 12 (8.3%)
Number of liver metastasis





< 5cm 14 (21.4%) 0.766 1.124 0.509-
2.482
0.772
≥ 5cm 16 (12.5%)
Peritoneal metastasis












T1, T2 4 (50.0%) 0.508 0.757 0.324-
1.767
0.519
T3, T4 26 (11.5%)
N metastasis: n(%)
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Liver is one of the most frequent sites of cancer metasta-
sis from gastrointestinal origin, and the major cause of
disease death from stomach cancer. The incidence of
synchronous liver metastasis from gastric cancer is
about 2.0%-9.6%, which is lower than that from colorec-
tal cancer. Approximately 0.4%-1.0% of these patients
could be treated by liver resection [7,10-12], with me-
dian survival of 5–31 months, 1-year survival rate of
15%-77%, and 5-year survival rate of 0%-38%, after hepa-
tectomy [6,7,13-17].
In the current study, 30 gastric cancer patients with
synchronous liver metastasis were simultaneously trea-
ted by both gastrectomy and hepatectomy, resulting a
median overall survival of 11.0 months, and 1-, 2-, 3-
and 5-year survival rates of 43.3%, 30.0%, 16.7% and
16.7%, respectively. Of particular note, 1 patient has a
disease-free survival of 107 months. Our multivariate
analysis found that preoperative tumor marker levels,
primary tumor size, tumor invasion depth, lymph nodes
metastasis, histological types, tumor emboli, ascites, liver
metastasis sizes all had no significant impact on survival,
but the number of liver metastasis and peritoneal metas-
tasis did have significant impact on survival.
It has been reported that gastric cancer prognosis
could be heavily influenced by many tumor pathological
features such as tumor invasion depth, lymph nodes
metastasis, pathological types and tumor emboli
[2,7,16,18].This study, however, did not find any signifi-
cant survival impact of these features, most probably
due to the fact that most previous studies included
patients with both synchronous and metachronous me-
tastases, but our study only focused on gastric cancer
patients with synchronous liver metastasis. Many other
studies since 2001 [2,3,6,13,16,19] also suggested that
pathological staging of the primary tumor did not have
significant impact on postoperative survival. Based on
these results, we believe that the routine clinico-
pathological features of the primary gastric cancer are
not major factors to impact on postoperative survival in
such patients with simultaneous resection of the gastric
cancer the liver metastasis.
In our study, we found that the number of liver metas-
tases and peritoneal metastasis are independent prog-
nostic factors for such patients with simultaneous
resection. Okano et al. [11] also found that patients with
Table 3 Multivariate Cox regression analysis
HR 95% CI P value
Peritoneal metastasis (P0 vs P1) 3.481 1.159-10.458 *0.026
Number of liver metastasis (1 vs 2–3) 2.262 1.056-5.349 *0.043
Figure 2 Comparison of survivals in patients with single liver metastasis and with multiple liver metastases. The Kaplan-Meier survival
curves showed a significantly longer survival time in patients with single liver metastasis than those with multiple liver metastases.
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survival rate than those with multiple liver metastases.
In addition, several other reports [6,16,20] also con-
firmed that the number of liver metastases is a major
prognostic factor. Ueda et al. [21] also found in 72 gas-
tric cancer patients with liver metastasis who had simul-
taneous resection, that patients with H1 and no
peritoneal metastasis had better survival, and such result
was repeated in a another similar study [19]. Because the
number of liver cancer metastases had strong correlation
with distribution of liver metastases (one lobe or two
lobes), the prognostic significance of liver cancer metas-
tasis distribution should be further investigated in large
scale clinical studies.
This study did not find any independent survival im-
pact of conventional pathological factors such as T stage
and N stage. Two major reasons may account for such
difference. The first concerns the disease status in our
series. This study included 30 patients of gastric cancer
with synchronous liver metastasis. In addition, there
were also 5 patients with peritoneal metastasis. There-
fore, all these patients were clinical stage IV. So it is not
surprising that the multivariate analysis found that the
number of liver metastases and peritoneal metastases
were the only two independent factors influencing sur-
vival. The second concerns the number of patients at
different T and N stages in this study. There were only 4
T1 and T2 cases, and 26 T4a cases. Similarly, there were
only 10 N0 and N1 cases out of the total 30 cases. The
smaller the number, the less statistical power they had.
The much smaller number of early T and early N casesmay also account for reason why they seemed not to have
influence on overall survival after multivariate analysis.
Among the 30 cases in this cohort, 6 patients had
increased AFP levels. These patients may had gastric
hepatoid carcinoma, which is a special subtype of gastric
cancer having very aggressive evolution. As the number
was not large enough, it is not possible to reach definite
conclusions on such patients. Accumulation of more
patients is warranted to make a more comprehensive
study of this patient subpopulation.
To our knowledge, our study is the largest series from
China to report on the simultaneous resection of gastric
cancer and liver metastasis. Our conclusion is that
patients with single liver metastasis and no peritoneal
metastasis could have better prognosis after simultan-
eous resection of both lesions. Although this was a
retrospective observational study without control group,
the results could be helpful to form rational treatment
approaches for such patients in China.
Liver metastasis is not the absolute contraindication
for gastric cancer surgery, but the following conditions
should be considered in selecting patients. First, the pri-
mary tumor could be resectable, and there should be no
superclavicular lymph nodes metastases or abnominal
aorta lymph nodes metastasis, no extrahepatic metastasis
Figure 3 Comparison of survivals in patients with versus without peritoneal metastasis. The Kaplan-Meier survival curves showed a
significantly shorter survival time in patients with versus without peritoneal metastasis.
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liver metastatic lesion, or lesions confined to one lobe of
the liver. Thirdly, the patient should have good organ
function reserve, with basically normal cardiac, pulmon-
ary, hepatic and renal functions. Absolute contraindica-
tions are extrahepatic metastases and unresectable liver
metastases. Whether preoperative chemotherapy could
be helpful to reduce liver metastasis or to enhance the
possibility of a clean margin resection, we did not con-
duct any study on this point. Future work should con-
sider this option.
Based on our results and literature study, we concluded
the for gastric cancer patients with liver metastasis: (1)
careful preoperative evaluation should be performed to
consider if curative resection is possible, and laparoscopy
could be considered if necessary; (2) for patients with syn-
chronous single liver metastasis, curative resection should
be the treatment of choice; (3) patients with peritoneal
metastasis had poor survival; (4) preoperative tumor mar-
ker levels should not be the criteria to judge whether sur-
gery should be performed; and (5) the pathological staging
of the primary tumor does on have significant impact on
postoperative survival.
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